Serum insulin-like growth factors and insulin-like growth factor-binding proteins: Clinical implications

Clinical Chemistry

Volumn 45, Issue 8 II, 1999, Pages 1384-1390

  Rosen, Clifford J ^a  

^a ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN C;

ANIMAL MODEL; BONE MASS; BONE TURNOVER; BREAST CANCER; CANCER RISK; CHRONIC DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; GROWTH HORMONE DEFICIENCY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; OSTEOPOROSIS; PROSTATE CANCER;

ANIMALS; BONE AND BONES; HUMANS; NEOPLASMS; OSTEOPOROSIS; RECEPTORS, SOMATOMEDIN; RISK FACTORS; SOMATOMEDINS;

ANIMALIA;

EID: 0032829933     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (75)

1. Salmon WD, Duaghaday WH. A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825-36.
2. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
3. Rudman D, Feller AG, Nelgrag HS. Effect of human GH in men over age 60. N Engl J Med 1990;323:52-60.
4. Zapf J, Schmid C, Froesch ER. Biological and immunological properties of IGF-I and IGF-II. Clin Endocrinol Metab 1984;13:7-12.
5. Zapf J, Froesch E. IGFs/somatomedins: structure, secretion, biological actions and physiological roles. Horm Res 1986;24: 121-30.
6. Mohan S, Baylink DJ. Autocrine and paracrine aspects of bone metabolism. Growth Gen Horm 1990;6:1-9.
7. Holman SR, Baxter RC. IGFBP-3: factors affecting binary and ternary complex formation. Growth Regul 1996;6:42-7.
8. Blum WF, Alberttson K, Roseberg S, Rnake MB. Serum levels of IGF-I and IGFBP-3 reflect spontaneous GH secretion. J Clin Endocrinol Metab 1993;76:1610-30.
9. Twigg SM, Baxter RC. IGF binding protein 5 forms and alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem 1998;273:6074-9.
10. Binoux M. IGF-binding protein-3 and acid-labile subunit: what is the pecking order? Eur J Endocrinol 1997;137:605-9.
11. Rajaram S, Baylink DJ, Mohan S. IGFBPs in serum and other biological fluids. Endocr Rev 1997;18:801-31.
12. Oh Y. IGFBPs and neoplastic models: new concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine 1997;7: 115-7.
13. LeRoith D, Werner H, Butner-Johnson D, Roberts CT. Molecular and cellular aspects of the IGF-I receptor. Endocr Rev 1995;16: 143-53.
14. LeRoith D, Parrizas M, Blakesley VA. IGF-I receptor and apoptosis. Endocrine 1997;7:103-5.
15. Baserga R, Resnicoff M, Dews M. The IGF-I receptor and cancer. Endocrine 1997;7:99-103.
16. Campbell PG, Novak TF, Yanoscik TB, McMaster JH. Involvement of the plasmin system in dissociation of IGFBP complex. Endocrinology 1992;130:1401-2.
17. Kanzaki S, Hilliker S, Baylink DJ, Mohan S. Evidence that human bone cells in culture produce IGFBP-4 and IGFBP-5 proteases. Endocrinology 1994;134:383-92.
18. Fowlkes J, Enghild J, Suzuki K, Nagase H. Matrix metalloproteinases degrade IGFBP-3 in dermal fibroblast cultures. J Biol Chem 1994;269:25742-6.
19. Canalis E, McCarthy TL, Centrella M. Growth factors and bone remodeling. J Clin Investig 1988;81:277-81.
20. Mohan S. IGF binding proteins in bone cell regulation. Growth Regul 1993;3:65-8.
21. Mohan S, Baylink DJ. Serum IGFBP-4 and IGFBP-5 in aging and age-associated diseases. Endocrine 1997;7:87-91.
22. Chan K, Spencer EM. General aspects of the IGFBPs. Endocrine 1997;7:95-7.
23. Rosen CJ, Conover C. Growth insulin like growth factor-I axis in aging: a summary of an NIA sponsored symposium. J Clin Endocrinol Metab 1997;82:3919-22.
24. Estivarez CE, Ziegler TR. Nutrition and the IGF system. Endocrine 1997;65-71.
25. Coverley JA, Baxter RC. Phosphorylation of IGFBPs. Mol Cell Endocrinol 1997;128:1-5.
26. Mohan S, Farley JR, Baylink DJ. Age-related changes in IGFBP-4 and IGFBP-5 in human serum and bone: implications for bone loss with aging. Prog Growth Factor Res 1995;6:465-73.
27. Cook F, Rosen CJ, Vereault D, Steffens C, Kessenich CR, Greenspan S, et al. Major changes in the circulatory IGF regulatory system after hip fracture surgery. J Bone Miner Res 1996;11:S327.
28. Veldhuis JD, Iranmanesh A, Weltman A. Elements in the pathophysiology of diminished GH secretion in aging humans. Endocrine 1997;7:41-8.
29. Toogood AA, O'Neil PA, Shalet SA. Beyond the somatopause: GHD in adults over age 60. J Clin Endocrinol Metab 1996;81:460-3.
30. Hoffman AR, Lieberman SA, Butterfield G, Thompson J, Hintz RRL, Ceda GP, Marcus P. Functional consequences of the somatopause and its treatment. Endocrine 1997;7:73-6.
31. Ho KY, Evans WS, Blizzard R, Veldhuis JD, Merriam G, Samojlik KE, et al. Effects of sex and age on the 24-h profiles of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-8.
32. Ahren B, Larsson H, Wilhemsson C, Nasman B, Olsson T. Regulation of circulating leptin in humans. Endocrine 1997;7:1-8.
33. Donahue LR, Hunter SJ, Sherblom AP, Rosen CJ. Age-related changes in serum IGFBPs in women. J Clin Endocrinol Metab 1990;71:575-9.
34. Gelato MC, Frost RA. IGFBP-3 functional and structural implications in aging and wasting syndromes. Endocrine 7:81-5.
35. Clemmons DR, Elgin RG, Han VKM, Casella SJ, D'Ercole AJ, Van Wyk JJ. Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin C/IGF-I. J Clin Investig 1986;77:1548-56.
36. Davis PY, Frazier CR, Shapiro JR, Fedarko NS. Age-related changes in effects of IGF-I on human osteoblast like cells. Biochem J 1997;324:753-60.
37. Grogean T, Vereault D, Millard PS, Rosen CJ. A comparative analysis of methods to measure IGF-I in human serum. Endocrinol Metab 1997;4:109-14.
38. Veldhuis JD, Kerr TY, South J, Weltman A, Weltman J, Clemmons DA, et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1995;82:3209-22.
39. Martha PM, Gooman KM, Blizzard RM, Rogol AD, Veldhuis JD. Endogenous growth hormone secretion and clearance in normal boys as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab 1992;74:336-44.
40. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases IGF-I in normal men. J Clin Endocrinol Metab 1993;77:776-80.
41. Andersen GH, Francis RM, Silly PL, Cooper CC. Sex hormones and osteopenia in men. Calcif Tissue Int 1998;62:185-8.
42. Bruch HR, Wolf L, Budde R, Romato G, Schweikert HU. Androstenedione metabolism in cultured human osteoblast-like cells. J Clin Endocrinol Metab 1992;75:101-5.
43. Carani C, Quirk C, Simoni M, Faustini, F, Serpente S, Boyd J, et al. Effect of testosterone and estradiol in a male with aromatase deficiency. N Engl J Med 1997;337:91-5.
44. Greendale GA, Delstein S, Barrett Connor E. Endogenous sex steroids and bone mineral density in older men and women. J Bone Miner Res 1997;12:1833-43.
45. Poehlman ET, Toth MJ, Ades PA, Rosen CJ. Menopause associated changes in plasma lipids insulin-like growth factor-I and blood pres sure: a longitudinal study. Eur J Clin Investig 1997;27:322-6.
46. LeBoff MS, Rosen CJ, Glowacki J. Changes in growth factors and cytokines in postmenopausal women. J Bone Miner Res 1995; 10:S241.
47. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, et al. Effects of estrogen and tamoxifen on Lp(a) and IGF-I in healthy postmenopausal women. Arterioscl Thromb 1994; 14:1586-92.
48. DePugola G, Lespite L, Grizzulli VA. IGF-I and DHEA-S in obese females. Int J Obes Rel Metab Disord 1993;11:481-3.
49. Morales AJ, Nolan JJ, Lukes CC, Yen SSC. Effects of replacement doses of DHEA in men and women. J Clin Endocrinol Metab 1994;78:1360-1.
50. Labrie F, Belanger A, Cusan L, Candan B. Physiological changes in DHEA are not reflected by serum levels of active androgens and estrogens but their metabolites. J Clin Endocrinol Metab 1997; 82:2403-9.
51. Commuzie AG, Blangero J, Mahaney MC, Haffner SM, Mitchell BD, Ster MP, MacCluer JW. Genetic and environmental correlates among hormone levels and measures of body fat accumulation and topography. J Clin Endocrinol Metab 1996;81:597-600.
52. Kao PC, Matheny AP, Lang CA. IGF-I comparisons in healthy twin children. J Clin Endocrinol Metab 1994;78:310-2.
53. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP 1 and IGFBP-3. J Clin Investig 1996;98:2612-5
54. Kurland E, Rackoff PJ, Adler RA, Bilezikian JP, Rogers J, Rosen CJ. Heritability of serum IGF-I and its relationship to bone density. The Endocrine Society, New Orleans, LA, June 15, 1998:S156.
55. Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J. et al. Circulating and skeletal insulin-like growth factor-1 (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. Bone 1997;2:217-23.
56. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, et al. Association between serum insulin growth factor-I (IGF-1) and a simple sequence repeat in IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998;83:2286-90.
57. Rosen CJ, Conover C. Growth hormone/insulin-like growth factor I axis in aging: a summary of a National Institutes of Aging-sponsored symposium. J Clin Endocrinol Metab 1997;82:3919-22.
58. Slootwigh MC. Growth hormone and bone. Horm Metab Res 1998;25:335-45.
59. Bing-you RG, Denis MG, Rosen CJ. Low bone mineral density in adults with previous hypothalamic pituitary tumors. Calcit Tissue Int 1993;52:183-7.
60. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PWF, Kiel DP. Association between insulin-like growth factor 1 and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab 1998;83:4257-62.
61. Bauer DC, Rosen C, Cauley J, Cummings SR, for the SOF Research Group. Low serum IGF-1 but not IGFBP-3 predicts hip and spine fracture: The study of osteoporotic fracture. Bone 1998;23:561.
62. Ensrud KE, Cauley J, Lipschutz R, Cummings SR. Weight change and fractures in older women. Study of osteoporotic fracture. Arch Intern Med 1997;157:857-63.
63. Reed BY, Zerwekh, JE, Sakhaee K, Breslau NA, Gottschalk F, Pak CYC. Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res 1995;10:1218-24.
64. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, et al. IGF-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1997;82:2799-805.
65. Kurland ES, Chan F, Vereault D, Rosen CJ, Bilezikian JP. Growth hormone IGF-I axis in men with idiopathic osteoporosis and reduced circulating levels of IGF-I. J Bone Miner Res 1996;11: S1323.
66. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Cell 1998;297:563-6.
67. Wolk A, Mantzoros, CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, et al. Insulin like growth factor 1 and prostate cancer risk: a population-based, case-control study. JNCI, 1998;90:911-95.
68. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998;351:1393-6.
69. Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekins C, Stampfer M. A prospective study of plasma levels of IGF I, IGFBP-3 and colon cancer risk among men. J Natl Cancer Inst 1999:in press.
70. Ng ST, Zhou J, Adesanya, OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997;3:1141-4.
71. Yang XF, Beamer W, Huynh HT, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 1996;56:1509-11.
72. Torrisi R, Parodi S, Fontana V, Pensa F, Caella C, Bareca A, et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer 1998;76:787-90.
73. Guvakova MA, Surmacz E. Tamoxifen interferes with the IGF-I receptor signaling pathway in breast cancer cells. Cancer Res 1997;57:2606-10.
74. Dunn SE, Kari FW, French J, Leninger JR, Travlos G, Wilson R, Barrett JC. Dietary restriction reduces IGF-I levels which modulates apoptosis, cell proliferation and tumor progression in p53 deficient mice. Cancer Res 1997;57:4667-72.
75. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban HR, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.